News

  • 14 February 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is designed to inhibit janus kinase 3, or JAK3, and tropomyosin receptor kinase A, or TrkA, with minimal to no systemic exposure. JAK3 is a validated target in psoriasis, atopic dermatitis and pruritus. JAK3 is required for immune cell development, and inhibiting JAK3 blocks the signaling of key cytokines, such as interleukin-17A, or IL-17A, IL-17F, IL-2 and tumor necrosis factor-alpha, or TNF-α, which results in a reduction in the severity of autoimmune and inflammatory diseases in which those cytokines play a pivotal role. TrkA is the high affinity receptor for nerve growth factor, or NGF, a known mediator of neurogenic inflammation and itch associated with psoriasis. This multicenter, randomized, double-blind, placebo- and comparator-controlled, intra-individual trial will evaluate the safety, tolerability and efficacy of SNA-125 compared to vehicle and other reference formulations in approximately 15 patients with chronic psoriasis.

  • 13 February 2018

    InDex Pharmaceuticals Holding AB (publ) today announced that the recently reported new mechanism of action data for the drug candidate cobitolimod has been selected for an oral presentation at the 13th congress of the European Crohn’s and Colitis Organisation (ECCO).

  • 8 February 2018

    Immunocore Limited, the soluble TCR company developing first-in-class biologics that have the potential to transform patient lives, today announces Dr Eliot Forster has stepped down as Chief Executive Officer.

  • 2 February 2018

    JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Laura A. Brenton as Vice President of Clinical and International Market Development. 

  • 8 January 2018

    TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory gastrointestinal and ocular diseases, today announces positive data from its Phase 1 study (TV03) with its oral formulation of TOP1288 for the treatment of ulcerative colitis (UC).